Why has the ODX share price climbed 25% in 3 days?

After a volatile 12 months, is the Omega Diagnostics (LON: ODX) share price set to soar on the promise of growing Covid antibody test sales?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shareholders in Omega Diagnostics Group (LSE: ODX) have suffered a volatile ride over the past 12 months. The stock is down 8% overall, but that hides a bigger story. As recently as March, the ODX share price was up at 100p. Then by 20 August, it had plunged to 42p.

Omega shares have started spiking upwards once more this week, gaining 28% in less than three market days. So what’s happening? And is this the start of another big climb? If it is, will it be sustainable this time? And, most important of all, should I buy? I can’t promise to answer all those questions, but I’ll offer some thoughts.

For the year ending 31 March, revenue fell 11% to £8.73m. And the firm recorded an adjusted pre-tax loss of £3.15m, compared to an adjusted loss of £0.4m the previous year.

Why the rise?

Omega did at least end the year with cash of £5.8m on the books. The ODX share price actually perked up a bit on the day of the results, but that didn’t last. So is it all down to the market’s love/hate relationship with companies in the Covid-19 testing field.

In its results statement, ODX said its sales were below expectations “mainly due to focus changing towards antigen testing in the UK where routine antibody testing was not recommended as previously anticipated.”

Aha, there might be something there. Just a few days ago, we heard that antibody tests are to become widely available to the UK public for the first time. Two tests, 28 days apart, could usher in the sales boost that Omega had been expecting in the previous year.

ODX share price valuation

That still doesn’t help me work out a fair valuation for Omega Diagnostics shares, mind. But in the long term, the share price will surely reflect the company’s bottom line profits. I’m reminded of Benjamin Graham’s famous statement that, in the short run, the market is like a voting machine, but in the long run it’s like a weighing machine.

Right now we don’t see a profitable track record to weigh up against the stock’s value. So the ODX share price is currently being driven by popularity, sentiment, and hope. That doesn’t make it wrong to buy now, not at all. No, it just makes it trickier to get it right and more of a risk. But for those who take the risk, I do think there’s a decent chance they’ll reap the rewards.

Sales surge?

Experts have been saying since the start of the pandemic that Covid-19 will be with us for longer than most people expect. I reckon it’s going to be even longer. I do think the demand for antibody tests could grow strongly, and the ODX share price could well follow.

Against that though, I don’t know how to guess at what proportion of antibody test sales will go Omega’s way. Or, for that matter, how it might translate into profit. And while Omega is continuing to develop new rapid Covid tests, so are many competitors.

As a relatively mature and low-risk investor, I won’t buy Omega Diagnostics shares now. But a younger me would probably invest a small sum.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »